Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Vicuron Pharmaceuticals
• Treatments: Anidulafungin; Echinocandins

Criteria

• Children ages 2-17 years with fever and neutropenia.

• The expected duration of neutropenia should be 10 days and due to cytotoxic chemotherapy or aplastic anemia.